for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Abbott Laboratories

ABT.N

Latest Trade

126.05USD

Change

-0.52(-0.41%)

Volume

1,452,990

Today's Range

125.83

 - 

127.58

52 Week Range

105.70

 - 

142.60

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
126.57
Open
126.75
Volume
1,452,990
3M AVG Volume
114.32
Today's High
127.58
Today's Low
125.83
52 Week High
142.60
52 Week Low
105.70
Shares Out (MIL)
1,768.29
Market Cap (MIL)
223,812.10
Forward P/E
24.90
Dividend (Yield %)
1.49

Next Event

Q4 2021 Abbott Laboratories Earnings Release

Latest Developments

More

Abbott Receives U.S. FDA Clearance For New Cardiac Mapping System To Improve How Doctors Treat Abnormal Heart Rhythms

Abbott Names Robert B. Ford Chairman Of The Board Miles D. White To Retire As Executive Chairman

Abbott Increases Quarterly Dividend For 50Th Consecutive Year

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Abbott Laboratories

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its products include a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The Company’s products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. It offers cardiovascular and metabolic products, including Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens, and Synthroid.

Industry

Medical Equipment & Supplies

Contact Info

100 Abbott Park Rd

ABBOTT PARK, IL

60064-3500

United States

+1.224.6676100

https://www.abbott.com/

Executive Leadership

Robert B. Ford

Chairman of the Board and Chief Executive Officer

Robert E. Funck

Chief Financial Officer, Executive Vice President - Finance

Hubert L. Allen

Executive Vice President, General Counsel, Secretary

Mary K. Moreland

Executive Vice President of Human Resources

John M. Capek

Executive Vice President - Ventures

Key Stats

2.00 mean rating - 24 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

30.6K

2019

31.9K

2020

34.6K

2021(E)

42.3K
EPS (USD)

2018

2.880

2019

3.240

2020

3.650

2021(E)

5.101
Price To Earnings (TTM)
31.19
Price To Sales (TTM)
5.29
Price To Book (MRQ)
6.50
Price To Cash Flow (TTM)
20.75
Total Debt To Equity (MRQ)
53.45
LT Debt To Equity (MRQ)
50.68
Return on Investment (TTM)
12.18
Return on Equity (TTM)
10.17

Latest News

Latest News

BRIEF-Abbott Laboratories Exec Says Expect Covid-19 Testing Demand Strength To Continue In The More Immediate Future- JPM Conf

* ABBOTT LABORATORIES EXEC SAYS SAW BIG SURGE IN THE UNITED STATES AND INTERNATIONALLY IN COVID-19 TEST DEMAND FOR DIAGNOSING AND SCREENING AROUND THANKSGIVING AND CHRISTMAS- JPM CONF

Abbott Labs CEO expects strong COVID-19 testing demand in near term

Abbott Laboratories Chief Executive Officer Robert Ford said on Tuesday demand for COVID-19 testing has surged globally and that sales of its tests should stay strong in the near term.

Consolidation of baby formula lawsuits sought in Illinois

More than 30 lawsuits claiming that cows' milk baby formula products cause a dangerous medical condition in premature infants have been filed against the makers of Enfamil and Similac in Illinois state courts since February, and plaintiffs’ firm Keller Lenkner is seeking...

Abbott sues DexCom over glucose-monitoring patent settlement, license

An Abbott Laboratories subsidiary focused on diabetes care sued rival DexCom in Delaware federal court for allegedly violating a 2014 settlement agreement and asked the court to declare that Abbott doesn't infringe its patents.

Abbott raises annual earnings outlook as COVID-19 test sales rebound

Abbott Laboratories said demand for its COVID-19 tests, especially rapid testing, rebounded as the U.S. wrestled with surging coronavirus cases during the quarter, prompting the company to raise its earnings forecast for the year.

BRIEF-Abbott Sold More Than 225 Mln COVID-19 Tests Globally In Q3: Conf Call

* ABBOTT CEO SAYS COMPANY SOLD MORE THAN 225 MILLION COVID TESTS GLOBALLY IN THIRD QUARTER: CONF CALL

Abbott quarterly profit surges more than 70%

Abbott Laboratories reported a 70.5% rise in quarterly profit on Wednesday, helped by strength in its medical device and diagnostics businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant of the coronavirus.

Abbott Labs unit recalling two COVID-19 lab test kits - FDA

A unit of Abbott Laboratories is recalling two COVID-19 laboratory test kits as they can potentially issue false positive results, the U.S. Food and Drug Administration (FDA) said on Thursday.

Abbott Labs unit recalling two COVID-19 test kits - FDA

A unit of Abbott Laboratories is recalling two COVID-19 test kits as they can potentially issue false positive results, the U.S. Food and Drug Administration (FDA) said on Thursday.

U.S. government to buy rapid COVID-19 tests from Abbott, Celltrion -official

The U.S. government has agreed to purchase rapid COVID-19 tests from Abbott Laboratories and Celltrion Inc to ship to nursing homes and other high risk populations as part of President Joe Biden's vaccinate or test plans, a senior administration official said on Tuesday.

Abbott Labs to pay $160 million over kickbacks, false diabetes claims to Medicare

Abbott Laboratories will pay $160 million to resolve claims that two of its units submitted false claims to Medicare by providing kickbacks to diabetes patients, including "free" or "no cost" glucose monitors, the U.S. Department of Justice said.

U.S. says Abbott units to pay $160 mln to resolve alleged false Medicare claims

Two units of Abbott Laboratories will pay $160 million to resolve claims they violated the federal False Claims Act by submitting false claims to Medicare, the U.S. Department of Justice said on Monday.

Abbott beats profit estimates as medical device sales rebound

Abbott Laboratories beat quarterly profit estimates on Thursday, driven by a rebound in its non-COVID-19 testing business and sales of its medical devices as vaccinations encouraged Americans to resume non-urgent procedures.

Abbott second-quarter profit surges as medical device sales rebound

Abbott Laboratories quarterly profit more than doubled on Thursday, due to strength in its diagnostics business and a rebound in medical devices sales.

St. Jude Medical to pay $27 million to settle allegations over heart devices

St. Jude Medical, which was acquired by Abbott Laboratories in 2017, has agreed to pay $27 million to settle allegations it knowingly sold defective heart devices, the U.S. Justice Department said on Thursday.

Abbott cuts 2021 profit forecast on lower COVID-19 testing demand

Abbott Laboratories on Tuesday cut its full-year 2021 profit forecast as it expects a sharp decline in revenue from its COVID-19 tests as more Americans get vaccinated, sending the medical device maker's shares down more than 6%.

Abbott sees 2021 profit below estimates on lower COVID-19 testing demand

Abbott Laboratories on Tuesday forecast 2021 profit below analysts' estimates, due to lower projected COVID-19 diagnostic testing demand.

Quest sees waning demand for COVID-19 tests, rebound in core U.S. business as pandemic subsides

Quest Diagnostics Inc on Thursday reported a first-quarter profit that exceeded Wall Street expectations as a recovery in its non-COVID-19 businesses offset a slowdown in coronavirus testing.

Abbott sales miss signals slowing COVID-19 tests demand as vaccinations take off

Abbott Laboratories fell short of first-quarter revenue estimates on Tuesday due to easing demand for some of its COVID-19 tests, stoking fears of slowing growth for the business as vaccinations gain steam across the globe.

Abbott first-quarter profit surges on COVID-19 test demand

Abbott Laboratories reported a more than threefold jump in quarterly profit on Tuesday, buoyed by robust demand for its COVID-19 test kits and growth in its diabetes and nutrition businesses.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up